Kepler Capital Markets set a CHF 87 target price on Novartis AG (VTX:NOVN) in a report released on Monday morning. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also recently issued reports on NOVN. J P Morgan Chase & Co set a CHF 70 price objective on Novartis AG and gave the company a neutral rating in a report on Saturday, May 20th. Goldman Sachs Group Inc set a CHF 80 price objective on Novartis AG and gave the company a neutral rating in a report on Saturday, May 20th. Jefferies Group LLC set a CHF 100 price objective on Novartis AG and gave the company a buy rating in a report on Saturday, May 20th. Morgan Stanley set a CHF 75 price objective on Novartis AG and gave the company a sell rating in a report on Saturday, May 20th. Finally, Barclays PLC set a CHF 65 price objective on Novartis AG and gave the company a sell rating in a report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of CHF 84.67.

Novartis AG (VTX:NOVN) opened at 80.90 on Monday. Novartis AG has a 1-year low of CHK 67.40 and a 1-year high of CHK 84.35. The stock has a 50 day moving average price of CHK 80.89 and a 200 day moving average price of CHK 78.05. The company has a market cap of CHK 189.54 billion and a P/E ratio of 29.54.

TRADEMARK VIOLATION NOTICE: “Novartis AG (NOVN) PT Set at CHF 87 by Kepler Capital Markets” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/01/novartis-ag-novn-pt-set-at-chf-87-by-kepler-capital-markets.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.